日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer

同时阻断PD-1和PD-L1免疫检查点可增强高级别浆液性卵巢癌的疗效

Changxin Wan ,Matthew P Keany ,Han Dong ,Linah F Al-Alem ,Unnati M Pandya ,Suzan Lazo ,Karsten Boehnke ,Katherine N Lynch ,Rui Xu ,Dominique T Zarrella ,Shengqing Gu ,Paloma Cejas ,Klothilda Lim ,Henry W Long ,Kevin M Elias ,Neil S Horowitz ,Colleen M Feltmate ,Michael G Muto ,Michael J Worley Jr ,Ross S Berkowitz ,Ursula A Matulonis ,Marisa R Nucci ,Christopher P Crum ,Bo R Rueda ,Myles Brown ,Xiaole Shirley Liu ,Sarah J Hill

Triaging abnormal cervical cancer screening tests using p16INK4a detection by ELISA on fresh cervical samples

使用 ELISA 检测新鲜宫颈样本中的 p16INK4a 对异常宫颈癌筛查检测进行分类

Shuk On Annie Leung, Sarah Feldman, Rajeshwari Kalyanaraman, Vignesh Shanmugam, Michael J Worley, Ross S Berkowitz, Neil S Horowitz, Colleen M Feltmate, Michael G Muto, Larissa J Lee, Martin T King, Jon I Einarsson, Mobolaji O Ajao, Kevin M Elias

Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions

Aurora 激酶抑制剂在 G2/M 检查点缺陷型 TP53 突变型子宫癌中的疗效增强与 LKB1-AKT-p53 相互作用的总和有关

Katherine N Lynch, Joyce F Liu, Nikolas Kesten, Kin-Hoe Chow, Aniket Shetty, Ruiyang He, Mosammat Faria Afreen, Liping Yuan, Ursula A Matulonis, Whitfield B Growdon, Michael G Muto, Neil S Horowitz, Colleen M Feltmate, Michael J Worley Jr, Ross S Berkowitz, Christopher P Crum, Bo R Rueda, Sarah J Hi

Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids

预测DNA修复抑制剂对短期患者来源卵巢癌类器官的反应

Sarah J Hill ,Brennan Decker ,Emma A Roberts ,Neil S Horowitz ,Michael G Muto ,Michael J Worley Jr ,Colleen M Feltmate ,Marisa R Nucci ,Elizabeth M Swisher ,Huy Nguyen ,Chunyu Yang ,Ryuji Morizane ,Bose S Kochupurakkal ,Khanh T Do ,Panagiotis A Konstantinopoulos ,Joyce F Liu ,Joseph V Bonventre ,Ursula A Matulonis ,Geoffrey I Shapiro ,Ross S Berkowitz ,Christopher P Crum ,Alan D D'Andrea

Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma

贝伐单抗、奥沙利铂和吉西他滨治疗复发性苗勒氏管癌的 II 期研究的安全性、有效性和生物标志物探索

Neil S Horowitz, Richard T Penson, Dan G Duda, Emmanuelle di Tomaso, Yves Boucher, Marek Ancukiewicz, Kenneth S Cohen, Suzanne Berlin, Carolyn N Krasner, Marsha A Moses, Rakesh K Jain